tbuckley/cabot-search huggingface dataset:
The performance and safety of motorized spiral enteroscopy, including in patients with surgically altered gastrointestinal anatomy: a multicenter prospective study
Authors: Abdulbaqi Al-Toma, Hanneke Beaumont, Jan Jacob Koornstra, Petra van Boeckel, Dorien Oude Hergelink, Jolein van der Kraan, Akin Inderson, Rogier de Ridder, Maarten Jacobs
Journal: Endoscopy (2022)

Background Data are scarce on the efficacy and safety of motorized spiral enteroscopy (MSE). No data are available on the utility of this technique in patients with surgically altered gastrointestinal (GI) anatomy. We aimed to evaluate the safety and efficacy of MSE in patients with suspected small-bowel disease, including those with surgically altered GI anatomy. Methods A multicenter prospective observational, uncontrolled study evaluated MSE in consecutive patients with suspected small-bowel pathology and an indication for diagnostic and/or therapeutic intervention. Results A total of 170 patients (102 men; median age 64 years, range 18–89) were included. The overall diagnostic yield was 64.1 %. Endotherapy was performed in 53.5 % of procedures. The median total procedure times for the antegrade and retrograde approaches were 45 minutes (interquartile range [IQR] 30–80) and 40 minutes (IQR 30–70), respectively. When total (pan)enteroscopy was intended, this was achieved at rate of 70.3 % (28.1 % by antegrade approach and 42.2 % by a bidirectional approach). Surgically altered GI anatomy was present in 34 /170 of all procedures (20.0 %) and in 11 /45 of the successful total enteroscopy procedures (24.4 %). Propofol sedation or general anesthesia were used in 92.9 % and 7.1 % of the procedures, respectively. Minor adverse events were observed in 15.9 % of patients, but there were no major adverse events. Conclusion MSE seems to be an effective and safe endoscopic procedure. Total (pan)enteroscopy can be achieved, in one or two sessions, even in the presence of surgically altered GI anatomy. The total procedure time is relatively short. For both antegrade and retrograde MSE procedures, propofol sedation seems sufficient and safe.
An Introduction to Gastro-Enterology
Journal: JAMA (1949)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Therapie in Einzeldarstellungen: Wissenschaftliche Grundlagen und praktische Anwendung.
Journal: JAMA (1931)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
A Multipronged, Evidence-Based Approach to Improving Mental Health Among Transgender and Gender-Diverse Youth
Authors: Brett Dolotina, Jack L. Turban
Journal: JAMA Network Open (2022)

Diana M. Tordoff, MPH; Jonathon W. Wanta, MD; Arin Collin, BA; Cesalie Stepney, PhD; David J. Inwards-Breland, MD, MPH; Kym Ahrens, MD, MPH
Genetic testing in prostate cancer management: Considerations informing primary care
Authors: Veda N. Giri, Todd M. Morgan, David S. Morris, Jacob E. Berchuck, Colette Hyatt, Mary‐Ellen Taplin
Journal: CA A Cancer Journal for Clinicians (2022)

Inherited genetic mutations can significantly increase the risk for prostate cancer (PC), may be associated with aggressive disease and poorer outcomes, and can have hereditary cancer implications for men and their families. Germline genetic testing (hereditary cancer genetic testing) is now strongly recommended for patients with advanced/metastatic PC, particularly given the impact on targeted therapy selection or clinical trial options, with expanded National Comprehensive Cancer Network guidelines and endorsement from multiple professional societies. Furthermore, National Comprehensive Cancer Network guidelines recommend genetic testing for men with PC across the stage and risk spectrum and for unaffected men at high risk for PC based on family history to identify hereditary cancer risk. Primary care is a critical field in which providers evaluate men at an elevated risk for PC, men living with PC, and PC survivors for whom germline testing may be indicated. Therefore, there is a critical need to engage and educate primary care providers regarding the role of genetic testing and the impact of results on PC screening, treatment, and cascade testing for family members of affected men. This review highlights key aspects of genetic testing in PC, the role of clinicians, with a focus on primary care, the importance of obtaining a comprehensive family history, current germline testing guidelines, and the impact on precision PC care. With emerging evidence and guidelines, clinical pathways are needed to facilitate integrated genetic education, testing, and counseling services in appropriately selected patients. There is also a need for providers to understand the field of genetic counseling and how best to collaborate to enhance multidisciplinary patient care.
SOCIETY PROCEEDINGS.
Journal: JAMA (1897)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Digitizing Tradition
Authors: Rebecca Voelker
Journal: JAMA (1994)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Rosacea treatment guideline for The Netherlands
Authors: E.J. Zuuren, M.M.D. Linden, B.W.M. Arents
Journal: British Journal of Dermatology (2020)

The authors of this research letter developed a treatment guideline for patients with rosacea in The Netherlands, based on a recently published review of all evidence on treating rosacea. The Dutch Society of Dermatology and Venereology funded the project and provided two staff members who supported the working group (WG). The WG consisted further of four dermatologists, a general practitioner, an ophthalmologist, a plastic surgeon, two skin therapists and a patient. For the process the most rigorous methodological standards were used. Ten health questions were covered in the guideline which assessed a range of self-care measures and treatment options, considering effectiveness and safety. Recommendations for these health questions were made by combining the evidence with values and preferences of patients, costs and availability. Recommendations are either strong (‘recommend’) or weak (‘consider’), and for or against a treatment. The authors presented the relevant treatments in an algorithm (Fig 1). Not mentioned are topical oxymetazoline for persistent redness (not available in The Netherlands) and those treatments with recommendations against. Considering rosacea has a negative impact on quality of life, a full chapter was dedicated to this in the guideline. In this chapter the authors recommended that doctors address quality of life, treatment satisfaction, social and professional functioning, and psychological well-being, in order to optimise treatment. In addition, a comprehensive patient information leaflet was made available on rosacea, its treatment and self-care. Figure 1Open in figure viewerPowerPoint Rosacea treatment algorithm. Consider = weak recommendation, Recommended = strong recommendation, b.i.d. = twice daily, q.d. = once daily. Erythema = redness. Papules = pimples. Pustules = pus-filled spots. Phyma = thickened nose. Telangiectasia= visible small blood vessels. This is a summary of the study: Rosacea treatment guideline for the Netherlands
The Subject of Continuous Vigilance
Authors: Arthur M. Langer
Journal: Environmental Health Perspectives (1974)

Asbestos disease in the occupational setting has been documented since the beginning of this century. Modern usage of asbestos fiber has brought with it concomitant and widespread contamination of the environment. The need to control asbestos is required in the forms of legislation and surveillance, to prevent the spread of asbestos disease into the general population.
Les filarioses pathogenes de l'homme; leur diagnostic et leur traitement actuel.
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Non-small molecule PROTACs (NSM-PROTACs): Protein degradation kaleidoscope
Authors: Sinan Ma, Jianai Ji, Yuanyuan Tong, Yuxuan Zhu, Junwei Dou, Xian Zhang, Shicheng Xu, Tianbao Zhu, Xiaoli Xu, Qidong You, Zhengyu Jiang
Journal: Acta Pharmaceutica Sinica B (2022)

The proteolysis targeting chimeras (PROTACs) technology has been rapidly developed since its birth in 2001, attracting rapidly growing attention of scientific institutes and pharmaceutical companies. At present, a variety of small molecule PROTACs have entered the clinical trial. However, as small molecule PROTACs flourish, non-small molecule PROTACs (NSM-PROTACs) such as peptide PROTACs, nucleic acid PROTACs and antibody PROTACs have also advanced considerably over recent years, exhibiting the unique characters beyond the small molecule PROTACs. Here, we briefly introduce the types of NSM-PROTACs, describe the advantages of NSM-PROTACs, and summarize the development of NSM-PROTACs so far in detail. We hope this article could not only provide useful insights into NSM-PROTACs, but also expand the research interest of NSM-PROTACs.
Second International Symposium on Cancer Therapy by Hyperthermia and Radiation
Journal: JNCI Journal of the National Cancer Institute (1976)

Second International Symposium on Cancer Therapy by Hyperthermia and Radiation Get access JNCI: Journal of the National Cancer Institute, Volume 57, Issue 6, December 1976, Page 1429, https://doi.org/10.1093/jnci/57.6.1429-a Published: 01 December 1976
A Virus-Infected, Reprogrammed Somatic Cell–Derived Tumor Cell (VIReST) Vaccination Regime Can Prevent Initiation and Progression of Pancreatic Cancer
Authors: Shuangshuang Lu, Zhe Zhang, Pan Du, Louisa S. Chard, Wenli Yan, Margueritte El Khouri, Zhizhong Wang, Zhongxian Zhang, Yongchao Chu, Dongling Gao, Qinxian Zhang, Lirong Zhang, Ai Nagano, Jun Wang, Claude Chelala, Jing Liu, Jiekai Chen, Pentao Liu, Yunshu Dong, Shengdian Wang, Xiaozhu Li, Jianzeng Dong, Nick R. Lemoine, Duanqing Pei, Yaohe Wang
Journal: Clinical Cancer Research (2019)

Abstract Purpose: Pancreatic cancer remains one of the most lethal cancers, and late detection renders most tumors refractory to conventional therapies. Development of cancer prophylaxis may be the most realistic option for improving mortality associated with this disease. Here, we develop a novel individualized prophylactic and therapeutic vaccination regimen using induced pluripotent stem cells (iPSC), gene editing, and tumor-targeted replicating oncolytic viruses. Experimental Design: We created a Virus-Infected, Reprogrammed Somatic cell-derived Tumor cell (VIReST) regime. iPSCs from healthy cells were induced to pancreatic tumor cells using in situ gene editing via stable provision of KRasG12D and p53R172H tumor driver mutations. These cells were preinfected with oncolytic Adenovirus (AdV) as prime or Vaccinia virus (VV) as boost, to improve vaccine immunogenicity, prior to delivery of vaccines in a sequential regime to young KPC transgenic mice, genetically programmed to develop pancreatic cancer, to prevent and delay disease development. Results: Tumor cells preinfected with oncolytic AdV as prime or VV as boost were the best regime to induce tumor-specific immunity. iPSC-derived tumor cells were highly related in antigen repertoire to pancreatic cancer cells of KPC transgenic mice, suggesting that an individual's stem cells can provide an antigenically matched whole tumor cell vaccine. The VIReST vaccination primed tumor-specific T-cell responses, resulting in delayed disease emergence and progression and significantly prolonged survival of KPC transgenic mice. Importantly, this regime was well-tolerated and nontoxic. Conclusions: These results provide both proof of concept and a robust technology platform for the development of personalized prophylactic cancer vaccines to prevent pancreatic malignancies in at-risk individuals.
Psychosocial Treatments for Bipolar Disorder in Children and Adolescents
Authors: Haley M. Brickman, Mary A. Fristad
Journal: Annual Review of Clinical Psychology (2022)

Evidence suggests that adjunctive psychosocial intervention for the treatment of pediatric bipolar spectrum disorders (BPSDs) is effective, feasible, and highly accepted as both an acute and maintenance treatment for youth with BPSD diagnoses as well as a preventive treatment for high-risk youth who are either asymptomatic or exhibit subsyndromal mood symptoms. Here, we provide a comprehensive review of all known evidence-based interventions, including detailed descriptions of treatment targets and core components, results of clinical trials, and updated research on mediators and moderators of treatment efficacy. Treatments are presented systematically according to level of empirical support (i.e., well established, probably efficacious, possibly efficacious, experimental, or questionable); upcoming and ongoing trials are included when possible. In line with a staging approach, preventive interventions are presented separately. Recommendations for best practices based on age, stage, and additional evidence-based child and family factors shown to affect treatment outcomes are provided.
Coxsackievirus A21 Synergizes with Checkpoint Inhibitors
Journal: Cancer Discovery (2017)

Treatment with a combination of a proprietary formulation of coxsackievirus and either an anti-CTLA-4 or anti-PD-1 checkpoint inhibitor yielded a higher response rate in phase I testing for melanoma than any of these drugs given on their own. Because the viral therapy adds little toxicity, it might prove an effective part of a dual regimen, according to interim trial data presented at the American Association for Cancer Research Annual Meeting 2017.
cRGD enables rapid phagocytosis of liposomal vancomycin for intracellular bacterial clearance
Authors: Guanghui Li, Mengke Wang, Tianhao Ding, Jing Wang, Tao Chen, Qianwen Shao, Kuan Jiang, Liping Wang, Yifei Yu, Feng Pan, Bin Wang, Xiaoli Wei, Jun Qian, Changyou Zhan
Journal: Journal of Controlled Release (2022)
Distinct B and NKT cell responses shape the delayed response to ChAdOx1 nCoV-19 vaccine in end-stage renal disease
Authors: Denise Utami Putri, Chiou-Feng Lin, Ching-Sheng Hung, Chun-Kai Huang, Tsong-Yih Ou, Chun-Yi Lai, Po-Chun Tseng, Chung-Yi Cheng, Chih-Hsin Lee
Journal: Journal of Infection (2022)
Comparative Effectiveness and Safety of Pertuzumab and Trastuzumab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy for Treatment of Metastatic Breast Cancer
Authors: Wei Fang Dai, Jaclyn M. Beca, Chenthila Nagamuthu, Ning Liu, Claire de Oliveira, Craig C. Earle, Maureen Trudeau, Rebecca E. Mercer, Kelvin K. W. Chan
Journal: JAMA Network Open (2022)

<h3>Importance</h3> To date, limited studies have examined the comparative outcomes of pertuzumab treatment in the real-world setting. End-of-study analyses of the CLEOPATRA trial found median overall survival (OS) of 57.1 months in patients receiving pertuzumab compared with 40.8 months in control patients, a benefit of 16.3 months. However, studies examining the real-world use of pertuzumab have found conflicting results. <h3>Objective</h3> To assess the real-world comparative effectiveness and safety of pertuzumab, trastuzumab, and chemotherapy for patients with metastatic breast cancer in Ontario, Canada. <h3>Design, Setting, and Participants</h3> A population-based retrospective comparative effectiveness research study was conducted. Patients receiving first-line treatments for metastatic breast cancer from January 1, 2008, to March 31, 2018, in Ontario were identified. Data analysis was performed from November 13, 2019, to August 1, 2021. Thirteen patients had received treatment before diagnosis or were not Ontario residents and were excluded from the analysis. Of the remaining 1823 patients identified, 912 received pertuzumab and 911 were control patients. Using propensity-score methods, 579 pairs of patients receiving pertuzumab were matched to those in the control group, resulting in a total of 1158 patients in the final cohort. <h3>Exposures</h3> Patients in the case group received pertuzumab with trastuzumab and chemotherapy and those in the control group received trastuzumab and chemotherapy. <h3>Main Outcomes and Measures</h3> Overall survival (the primary outcome) and hazard ratios (HRs) were calculated using Kaplan-Meier and Cox proportional hazards regression methods. Secondary outcomes included cumulative incidence of safety end points including resource use and adverse events. Follow-up duration was up to 5 years from the start of therapy, with maximum follow-up to March 31, 2019. <h3>Results</h3> Of the 1158 matched patients (579 pairs) receiving pertuzumab and controls, 1151 (99%) were women (mean [SD] age, 58.2 [12.97] years). The median OS was higher in patients receiving pertuzumab (40.2; 95% CI, 35.6-47.8 months) than in the control patients (25.3; 95% CI, 22.8-27.6 months), a median OS improvement of 14.9 months. Pertuzumab was associated with reduced mortality (HR, 0.66; 95% CI, 0.57-0.79). The cumulative incidence of direct hospitalization at 1 year was lower among patients receiving pertuzumab (11.7%) compared with the control patients (19.0%) (<i>P</i> &lt; .001). <h3>Conclusions and Relevance</h3> Although the median OS in both the pertuzumab and control groups were shorter in this study than those observed in the CLEOPATRA trial, there appears to be a similar significant OS benefit with pertuzumab in the real-world setting.
The endothelial Dll4–muscular Notch2 axis regulates skeletal muscle mass
Authors: Shin Fujimaki, Tomohiro Matsumoto, Masashi Muramatsu, Hiroshi Nagahisa, Naoki Horii, Daiki Seko, Shinya Masuda, Xuerui Wang, Yoko Asakura, Yukie Takahashi, Yuta Miyamoto, Shingo Usuki, Kei-ichiro Yasunaga, Yasutomi Kamei, Ryuichi Nishinakamura, Takashi Minami, Takaichi Fukuda, Atsushi Asakura, Yusuke Ono
Journal: Nature Metabolism (2022)